Neurocrine Biosciences (LTS:0K6R) Ending Cash Position : $202 Mil (As of Mar. 2025)

View and export this data going back to 2018. Start your Free Trial

What is Neurocrine Biosciences Ending Cash Position?

Neurocrine Biosciences's Ending Cash Position for the quarter that ended in Mar. 2025 was $202 Mil.

Neurocrine Biosciences's quarterly Ending Cash Position declined from Sep. 2024 ($357 Mil) to Dec. 2024 ($241 Mil) and declined from Dec. 2024 ($241 Mil) to Mar. 2025 ($202 Mil).

Neurocrine Biosciences's annual Ending Cash Position declined from Dec. 2022 ($271 Mil) to Dec. 2023 ($259 Mil) and declined from Dec. 2023 ($259 Mil) to Dec. 2024 ($241 Mil).

Neurocrine Biosciences Ending Cash Position Historical Data

The historical data trend for Neurocrine Biosciences's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neurocrine Biosciences Ending Cash Position Chart

Neurocrine Biosciences Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Ending Cash Position

Get a 7-Day Free Trial

190.30

344.00

270.70

259.10

241.00

Neurocrine Biosciences Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Ending Cash Position	Get a 7-Day Free Trial															404.30	147.70	357.10	241.00	202.10

Neurocrine Biosciences Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Neurocrine Biosciences's Ending Cash Position for the fiscal year that ended in Dec. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	259.1	+	-18.1
	=	241

Neurocrine Biosciences's Ending Cash Position for the quarter that ended in Mar. 2025 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	241	+	-38.9
	=	202

Neurocrine Biosciences Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Neurocrine Biosciences's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Neurocrine Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Neurocrine Biosciences Inc (LTS:0K6R) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

NBIX:USA NB3:Germany N1BI34:Brazil

Address

6027 Edgewood Bend Court, San Diego, CA, USA, 92130

Website

https://www.neurocrine.com

Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.

Neurocrine Biosciences Headlines

No Headlines